Cabio Biotech (Wuhan) Co., Ltd.
SHH: 688089.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dewei Yi
- Employees
- 565
- Headquarters
- Wuhan, China
- IPO year
- 2019
- Market cap
- CN¥2.7B
- Website
- https://www.cabio.cn
Loading 688089…
Loading profile data…Frequently asked questions about 688089
What does Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) do?
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, econom...
Where does 688089.SS trade?
Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) trades on the Shanghai Stock Exchange.
What sector is 688089.SS in?
Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cabio Biotech (Wuhan) Co., Ltd.?
Dewei Yi is the chief executive officer of Cabio Biotech (Wuhan) Co., Ltd. (688089.SS).
Where is Cabio Biotech (Wuhan) Co., Ltd. headquartered?
Cabio Biotech (Wuhan) Co., Ltd. is headquartered in China.
Does 688089.SS pay a dividend?
Yes — Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) paid a trailing twelve-month dividend of CNY 0.20 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688089.SS go public?
Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) completed its initial public offering in 2019.